Citations

Citations to this article as recorded by  

• Big Data Research in the Field of Endocrine Diseases Using the Korean National Health Information Database
  Sun Wook Cho, Jung Hee Kim, Han Seok Choi, Hwa Young Ahn, Mee Kyoung Kim, Eun Jung Rhee
  Endocrinology and Metabolism.2023; 38(1): 10.     CrossRef
• Cushing Syndrome
  Martin Reincke, Maria Fleseriu
  JAMA.2023; 330(2): 170.     CrossRef
• Clinical Biology of the Pituitary Adenoma
  Shlomo Melmed, Ursula B Kaiser, M Beatriz Lopes, Jerome Bertherat, Luis V Syro, Gerald Raverot, Martin Reincke, Gudmundur Johannsson, Albert Beckers, Maria Fleseriu, Andrea Giustina, John A H Wass, Ken K Y Ho
  Endocrine Reviews.2022; 43(6): 1003.     CrossRef

Management of pituitary tumors is multidisciplinary, with medical therapy playing an increasingly important role. With the exception of prolactin-secreting tumors, surgery is still considered the first-line treatment for the majority of pituitary adenomas. However, medical/pharmacological therapy plays an important role in controlling hormone-producing pituitary adenomas, especially for patients with acromegaly and Cushing disease (CD). In the case of non-functioning pituitary adenomas (NFAs), pharmacological therapy plays a minor role, the main objective of which is to reduce tumor growth, but this role requires further studies. For pituitary carcinomas and atypical adenomas, medical therapy, including chemotherapy, acts as an adjuvant to surgery and radiation therapy, which is often required to control these aggressive tumors. In the last decade, knowledge about the pathophysiological mechanisms of various pituitary adenomas has increased, thus novel medical therapies that target specific pathways implicated in tumor synthesis and hormonal over secretion are now available. Advancement in patient selection and determination of prognostic factors has also helped to individualize therapy for patients with pituitary tumors. Improvements in biochemical and “tumor mass” disease control can positively affect patient quality of life, comorbidities and overall survival. In this review, the medical armamentarium for treating CD, acromegaly, prolactinomas, NFA, and carcinomas/aggressive atypical adenomas will be presented. Pharmacological therapies, including doses, mode of administration, efficacy, adverse effects, and use in special circumstances are provided. Medical therapies currently under clinical investigation are also briefly discussed.

Citations

Citations to this article as recorded by  

• Multiomics Approach to Acromegaly: Unveiling Translational Insights for Precision Medicine
  Kyungwon Kim, Cheol Ryong Ku, Eun Jig Lee
  Endocrinology and Metabolism.2023; 38(5): 463.     CrossRef
• PDCD10 promotes the aggressive behaviors of pituitary adenomas by up-regulating CXCR2 and activating downstream AKT/ERK signaling
  Jingdian Liu, Junwen Wang, Weidong Tian, Yu Xu, Ran Li, Kai Zhao, Chao You, Yuan Zhu, Joerg Walter Bartsch, Hongquan Niu, Huaqiu Zhang, Kai Shu, Ting Lei
  Aging.2022; 14(15): 6066.     CrossRef
• LncRNA MYMLR promotes pituitary adenoma development by upregulating carbonyl reductase 1 via sponging miR-197-3p
  Tuo Wang, Ping Mao, Yan Zhang, Bo Cui, Mao-De Wang, Ya Li, Ke Gao
  Anti-Cancer Drugs.2022; 33(10): 1058.     CrossRef
• Comparative Proteomic Study Shows the Expression of Hint-1 in Pituitary Adenomas
  Carolina Carrillo-Najar, Daniel Rembao-Bojórquez, Martha L. Tena-Suck, Sergio Zavala-Vega, Noemí Gelista-Herrera, Miguel A. Ramos-Peek, Juan L. Gómez-Amador, Febe Cazares-Raga, Fidel de la Cruz Hernández-Hernández, Alma Ortiz-Plata
  Diagnostics.2021; 11(2): 330.     CrossRef
• Recent Understanding and Future Directions of Recurrent Corticotroph Tumors
  José Miguel Hinojosa-Amaya, César Ernesto Lam-Chung, Daniel Cuevas-Ramos
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• What to Do with Incidentally Discovered Pituitary Abnormalities?
  Fabienne Langlois, Maria Fleseriu
  Medical Clinics of North America.2021; 105(6): 1081.     CrossRef
• Aggressive prolactinoma (Review)
  Ana Valea, Florica Sandru, Aida Petca, Mihai Dumitrascu, Mara Carsote, Razvan-Cosmin Petca, Adina Ghemigian
  Experimental and Therapeutic Medicine.2021;[Epub]     CrossRef
• Diagnosis and Treatment of Pituitary Adenomas
  O. A. Beylerli, Zhao Shiguang, I. F. Gareev, Chen Xin
  Creative surgery and oncology.2020; 9(4): 311.     CrossRef
• Management of patients with persistent or recurrent Cushing’s disease after initial pituitary surgery
  Cristina Capatina, José Miguel Hinojosa-Amaya, Catalina Poiana, Maria Fleseriu
  Expert Review of Endocrinology & Metabolism.2020; 15(5): 321.     CrossRef
• Modern principles of the diagnosis and conservative treatment of Cushing disease
  Ashraf Abdali, Ludmila Astafeva, Pavel Kalinin, Yuriy Trunin, I. V. Chernov, G. E. Сhmutin, Abdali Badshahzar, GulSharif Sherzad, Simfukwe Keith
  Vestnik nevrologii, psihiatrii i nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery).2020; (10): 67.     CrossRef
• Effects of Oxytocin on Cell Proliferation in a Corticotroph Adenoma Cell Line
  Jung Soo Lim, Young Woo Eom, Eun Soo Lee, Hyeong Ju Kwon, Ja-Young Kwon, Junjeong Choi, Choon Hee Chung, Young Suk Jo, Eun Jig Lee
  Endocrinology and Metabolism.2019; 34(3): 302.     CrossRef
• Pituitary Adenomas: What Are the Key Features? What Are the Current Treatments? Where Is the Future Taking Us?
  Domenico Solari, Rosario Pivonello, Chiara Caggiano, Elia Guadagno, Carmela Chiaramonte, Giovanni Miccoli, Luigi M. Cavallo, Marialaura Del Basso De Caro, Annamaria Colao, Paolo Cappabianca
  World Neurosurgery.2019; 127: 695.     CrossRef
• Expression of Cyclin E/Cdk2/p27Kip1 in Growth Hormone Adenomas
  Wei Dong, Haibo Zhu, Hua Gao, Wenjian Shi, Yu Zhang, Hongyun Wang, Chuzhong Li, Guidong Song, Yazhuo Zhang
  World Neurosurgery.2019; 121: e45.     CrossRef
• Acromegaly
  Annamaria Colao, Ludovica F. S. Grasso, Andrea Giustina, Shlomo Melmed, Philippe Chanson, Alberto M. Pereira, Rosario Pivonello
  Nature Reviews Disease Primers.2019;[Epub]     CrossRef
• Differenzialdiagnostik und Therapie der Hypophysenadenome
  M. Hlaváč, F. Sommer, G. Karpel-Massler, R. Wirtz, T. Hoffmann, A. Paľa
  HNO.2019; 67(4): 307.     CrossRef
• Medical Management of Cushing’s Syndrome: Current and Emerging Treatments
  José Miguel Hinojosa-Amaya, Daniel Cuevas-Ramos, Maria Fleseriu
  Drugs.2019; 79(9): 935.     CrossRef
• Aggressive and Malignant Prolactinomas
  Nicoleta Cristina Olarescu, Luis G. Perez-Rivas, Federico Gatto, Thomas Cuny, Maria A. Tichomirowa, Gianluca Tamagno, Manuel D. Gahete
  Neuroendocrinology.2019; 109(1): 57.     CrossRef
• New Insights in Cushing Disease Treatment With Focus on a Derivative of Vitamin A
  Mariana Fuertes, Julieta Tkatch, Josefina Rosmino, Leandro Nieto, Mirtha Adriana Guitelman, Eduardo Arzt
  Frontiers in Endocrinology.2018;[Epub]     CrossRef
• Prenatal alcohol exposure increases the susceptibility to develop aggressive prolactinomas in the pituitary gland
  Shaima Jabbar, Kenneth Reuhl, Dipak K. Sarkar
  Scientific Reports.2018;[Epub]     CrossRef
• Aggressive and malignant pituitary tumours: state-of-the-art
  Dorota Dworakowska, Ashley B Grossman
  Endocrine-Related Cancer.2018; 25(11): R559.     CrossRef
• Epidemiología y caracterización general de los tumores cerebrales primarios en el adulto
  Maria Isabel Ocampo Navia, Juan Carlos Gómez Vega, Oscar Hernando Feo Lee
  Universitas Médica.2018;[Epub]     CrossRef
• Triptolide inhibits pituitary adenoma cell viability, migration and invasion via ADAM12/EGFR signaling pathway
  Junwen Wang, Zhuo Zhang, Ran Li, Wei Sun, Juan Chen, Huaqiu Zhang, Kai Shu, Ting Lei
  Life Sciences.2018; 194: 150.     CrossRef
• Emerging roles of bexarotene in the prevention, treatment and anti-drug resistance of cancers
  Danyang Shen, Xiaoming Yu, Yan Wu, Yuanlei Chen, Gonghui Li, Feng Cheng, Liqun Xia
  Expert Review of Anticancer Therapy.2018; 18(5): 487.     CrossRef
• New Molecular Targets for Treatment of Cushing’s Disease
  Elizabeth Foulkes, John Newell-Price
  Endocrinology and Metabolism Clinics of North America.2018; 47(2): 367.     CrossRef
• Pituitary-Directed Therapies for Cushing’s Disease
  Fabienne Langlois, Jennifer Chu, Maria Fleseriu
  Frontiers in Endocrinology.2018;[Epub]     CrossRef
• Updates in Diagnosis and Treatment of Acromegaly
  Roula Zahr, Maria Fleseriu
  European Endocrinology.2018; 14(2): 57.     CrossRef
• Root cause analysis of diagnostic and surgical failures in the treatment of suspected Cushing’s disease
  Hasan A. Zaidi, David L. Penn, David J. Cote, Edward R. Laws
  Journal of Clinical Neuroscience.2018; 53: 153.     CrossRef

Cushing's disease (CD) is a rare disorder characterized by the overproduction of adrenocorticotropic hormone due to a pituitary adenoma that ultimately stimulates excessive cortisol secretion from the adrenal glands. Prior to the detection of pituitary adenomas, various clinical signs of CD such as central obesity, moon face, hirsutism, and facial plethora are usually already present. Uncontrolled hypercortisolism is associated with metabolic, cardiovascular, and psychological disorders that result in increased mortality. Hence, the early detection and treatment of CD are not only important but mandatory. Because its clinical manifestations vary from patient to patient and are common in other obesity-related conditions, the precise diagnosis of CD can be problematic. Thus, the present set of guidelines was compiled by Korean experts in this field to assist clinicians with the screening, diagnoses, and treatment of patients with CD using currently available tests and treatment modalities.

Citations

Citations to this article as recorded by  

• Diet quality and dietary acid load in relation to cardiovascular disease mortality: Results from Fasa PERSIAN cohort study
  Sahar Fereidouni, Najmeh Hejazi, Reza Homayounfar, Mojtaba Farjam
  Food Science & Nutrition.2023; 11(3): 1563.     CrossRef
• Role of computed tomography in predicting adrenal adenomas with cortisol hypersecretion
  Chan Kyo Kim, Kyung A Kang, Young Lyun Oh, Sung Yoon Park
  The British Journal of Radiology.2023;[Epub]     CrossRef
• Dietary acid load and mortality from all causes, CVD and cancer: results from the Golestan Cohort Study
  Ehsan Hejazi, Hadi Emamat, Maryam Sharafkhah, Atoosa Saidpour, Hossein Poustchi, Sadaf Sepanlou, Masoud Sotoudeh, Sanford Dawsey, Paolo Boffetta, Christian C Abnet, Farin Kamangar, Arash Etemadi, Akram Pourshams, Akbar Fazeltabar Malekshah, Paul Berennan,
  British Journal of Nutrition.2022; 128(2): 237.     CrossRef
• Forty Years Together, New Leap Forward! The 40th Anniversary of the Korean Endocrine Society
  Jong Chul Won, Ki-Hyun Baek
  Endocrinology and Metabolism.2022; 37(6): 851.     CrossRef
• Pituitary adenomas: current principles of diagnosis and treatment
  L. I. Astafyeva, I. V. Chernov, I. V. Chekhonin, E. I. Shults, I. N. Pronin, P. L. Kalinin
  Russian journal of neurosurgery.2021; 22(4): 94.     CrossRef
• Metabolic changes in serum steroids for diagnosing and subtyping Cushing’s syndrome
  Chang Ho Ahn, Chaelin Lee, Jaeyoon Shim, Sung Hye Kong, Su-jin Kim, Yong Hwy Kim, Kyu Eun Lee, Chan Soo Shin, Jung Hee Kim, Man Ho Choi
  The Journal of Steroid Biochemistry and Molecular Biology.2021; 210: 105856.     CrossRef
• Application of different variants of endoscopic transphenoidal removal of corticotropinomas in order to increase the frequency and duration of remission
  A. Ashraf, I. V. Chernov, A. N. Shkarubo, M. A. Kutin, D. V. Fomichev, O. I. Sharipov, Yu. Yu. Trunin, D. N. Andreev, A. A. Abdilatipov, L. I. Astafieva, B. Abdali, A. B. Kurnosov, G. E. Chmutin, Kalinin P. L. Kalinin P. L.
  Vestnik nevrologii, psihiatrii i nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery).2021; (2): 143.     CrossRef
• Modern aspects of surgery for cushing’s disease
  A. Abdali, L.I. Astafeva, Yu.Yu. Trunin, I.V. Chernov, Yu.G. Sidneva, A.A. Abdilatipov, P.L. Kalinin
  Voprosy neirokhirurgii imeni N.N. Burdenko.2021; 85(4): 111.     CrossRef
• Pituitary microadenomas — current diagnostic and treatment methods
  L.I. Astafyeva, B.A. Kadashev, Yu.G. Sidneva, I.V. Chernov, P.L. Kalinin
  Voprosy neirokhirurgii imeni N.N. Burdenko.2020; 84(2): 110.     CrossRef
• Usefulness of prolactin measurement in inferior petrosal sinus sampling with desmopressin for Cushing’s syndrome
  Hamideh Akbari, Mohammad Ghorbani, Maryam Kabootari, Ali Zare Mehrjardi, Mohammad Reza Mohajeri Tehrani, Mojtaba Malek, Mohammad E. Khamseh
  British Journal of Neurosurgery.2020; 34(3): 253.     CrossRef
• Hormonal aggressiveness according to the expression of cellular markers in corticotroph adenomas
  Jung Soo Lim, Mi-Kyung Lee, Eunhee Choi, Namki Hong, Soo Il Jee, Sun Ho Kim, Eun Jig Lee
  Endocrine.2019; 64(1): 147.     CrossRef
• Clinical Parameters to Distinguish Silent Corticotroph Adenomas from Other Nonfunctioning Pituitary Adenomas
  Daham Kim, Cheol Ryong Ku, Se Hee Park, Ju Hyung Moon, Eui Hyun Kim, Sun Ho Kim, Eun Jig Lee
  World Neurosurgery.2018; 115: e464.     CrossRef
• Blood Tests for the Diagnosis of Adrenal Diseases
  Seon-Ah Cha, Sung-Dae Moon
  The Korean Journal of Medicine.2018; 93(6): 532.     CrossRef
• Choosing wisely: la lista del gruppo di studio Endocrinologia e Malattie del Metabolismo della Società Italiana di Patologia Clinica e Medicina di Laboratorio
  Romolo M. Dorizzi, Anna Ferrari, Marina Vitillo, Beatrice Caruso, Claudio Cocco, Erennio Ciotoli, Federica D’Aurizio, Elisa Esposito, Germana Giannone, Giulio Ozzola, Ottavia Porzio, Emanuela Toffalori, Renato Tozzoli
  La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine.2016; 12(2): 81.     CrossRef
• Surgical management of adrenocorticotropic hormone-secreting pituitary adenomas
  Edwin S Kulubya, Daniel A Donoho, John D Carmichael, Gabriel Zada
  International Journal of Endocrine Oncology.2016; 3(1): 41.     CrossRef